Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

Leukemia Research

Volumn 36, Issue 1, 2012, Pages 59-66

  Black, John L ^a   Litzow, Mark R ^a   Hogan, William J ^a   O'Kane, Dennis J ^a   Walker, Denise L ^a   Lesnick, Timothy G ^a   Kremers, Walter K ^a   Avula, Rajeswari ^a   Ketterling, Rhett P ^a  

^a MAYO CLINIC   (United States)

Author keywords

ABCC4; Blood or marrow transplantation; Cyclophosphamide; CYP2B6; CYP2C19; SOD2

Indexed keywords

ABCC4 PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL ENZYME; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG MEGADOSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INFANT; LEUKEMIA; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SUPEROXIDE DISMUTASE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 83555173440     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.020     Document Type: Article

References (29)

1. Weisdorf D., Spellman S., Haagenson M., Horowitz M., Lee S., Anasetti C., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biology of Blood and Marrow Transplantation 2008, 14:748-758.
2. Nakajima M., Komagata S., Fujiki Y., Kanada Y., Ebi H., Itoh K., et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenetics and Genomics 2007, 17:431-445.
3. Xie H., Griskevicius L., Stahle L., Hassan Z., Yasar U., Rane A., et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. European Journal of Pharmaceutical Studies 2006, 27:54-61.
4. Xie H.-J., Yasar U., Lundgren S., Griskevivius L., Terelius Y., Hassan M., et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. The Pharmacogenomics Journal 2003, 3:53-61.
5. Zukunft J., Lang T., Richter T., Hirsch-Ernst K., Nussler A., Klein K., et al. A natural CYP2B6 TATA box polymorphism (-82T-C) leading to enhanced transcription and relocation of the transcriptional start site. Molecular Pharmacology 2005, 67:1772-1782.
6. Klein K., Lang T., Saussele T., Barbosa-Sicard E., Schunck W.-H., Ekchelbaum M., et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenetics and Genomics 2005, 15:861-873.
7. Kirchheiner J., Brøsen K., Dahl M., Gram L., Kasper S., Roots I., et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatry Scandinavia 2001, 104:173-192.
8. Gaedigk A., Simon S., Pearce R., Bradford L., Kennedy M., Leeder J. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical Pharmacology & Therapeutics 2008, 83:234-242.
9. Steimer W., Zopf K., Von Amelunxen S., Pfeiffer H., Bachofer J., Popp J., et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CY2D6 extensive and intermediate metabolizers. Clinical Chemistry 2004, 50:1623-1633.
10. Low S.-K., Kiyotani K., Mushiroda T., Daigo Y., Nakamura A., Zembutsu H. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. Journal of Human Genetics 2009, 54:564-571.
11. Sutton A., Khoury H., Prip-Buus C., Cepanec C., Pessayre D., Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003, 13:145-157.
12. Scheike T., Zhang M.-J. Analyzing competing risk data using the R timereg package. Journal of Statistical Software 2011, 38:1-15.
13. Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25:1679-1691.
14. Takada K., Arefayene M., Desta Z., Yarboro C., Boumpas D., Balow J., et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis and Rheumatism 2004, 50:2202-2210.
15. Lang T., Klein K., Fischer J., Nussler A., Neuhaus P., Hofmann U., et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001, 11:399-415.
16. Rocha V., Porcher R., Fernandes J., Filion A., Bittencourt H., Silva W., et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009, 23:545-556.
17. Elmaagacli A., Koldehoff M., Steckel N., Trenschel R., Ottinger H., Beelen D. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplantation 2007, 40:659-664.
18. Timm R., Kaiser R., Lotsch J., Heider U., Sezer O., Weisz K., et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. The Pharmacogenomics Journal 2005, 5:365-373.
19. Oberley L., Buettner G. Role of superoxide dismutase in cancer: a review. Cancer Research 1979, 39:1141-1149.
20. Glynn S., Boersma B., Howe T., Edvardsen H., Geisler S., Goodman J., et al. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research 2009, 15:4165-4173.
21. Ambrosone C., Ahn J., Singh K., Rezaishiraz H., Furberg H., Sweeney C., et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD CAT) and survival after treatment for breast cancer. Cancer Research 2005, 65:1105-1111.
22. Bewick M., Conlon M., Lafrenie R. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Research & Treatment 2008, 111:93-101.
23. Conklin K. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integrative Cancer Therapy 2004, 3:294-300.
24. Hung R., Boffetta P., Brennan P., Malaveille C., Gelatti U., Placidi D., et al. Genetic polymorphisms of MPO, COMT, MnSOD. NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 2004, 25:973-978.
25. Ambrosone C., Freudenheim J., Thompson P., Bowman E., Vena J., Marshall J., et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Research 1999, 59:602-606.
26. Woodson K., Tangrea J., Lehman T., Modali R., Taylor K., Snyder K., et al. Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes and Control 2003, 14:513-518.
27. Tian Q., Zhang J., Tan T., Chan E., Chan W.D., Boelsterli S., et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharmaceutical Research 2005, 22:1837-1853.
28. Czerwinski M., Gibbs J., Slattery J. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metabolism and Disposition 1996, 24:1015-1019.
29. Elhasid R., Kirvoy N., Rowe J., Sprecher E., Adler L., Elkin H., et al. Influence of glutathione S-transferase A1, P1, M1. T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatric Blood Cancer 2010, 29:1-8.